

AF\$  
Can 1/16/95

Docket No. 43016-A-PCT-US/JPW/SHS

In re application of: Philip Livingston and Friedhelm Helling

Serial No.: 08/196,154

Group Art Unit: 1806

Filed: November 16, 1998 Examiner: A. Caputa

For: GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

July 21, 1999

S I R:

Transmitted herewith is an amendment to the above-identified application.

  X   Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

       a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

       No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	28	- * 25	= *** 3	x	9	18	= 27	0
Independent Claims	12	- ** 3	= *** 9	x	39	78	= 351	0
Multiple Dependent Claims(s) Presented <u>      </u> Yes <u>  X  </u> No For First Time:					130	260	0	0
					TOTAL ADDITIONAL FEE \$ 378.00			

\*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\*If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

RECEIVED  
TECH CENTER 1800/2900  
89 JUL 29 AM 10:49

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/196,154  
Filed: November 16, 1995

Amendment Transmittal Letter  
Page 2

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

\_\_\_\_\_ Please charge Deposit Account No. \_\_\_\_\_  
in the amount of \$ \_\_\_\_\_.

X A check in the amount of \$ 1,683.00 is enclosed.

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125. Three copies of this sheet are enclosed.

X Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.

X Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,

Albert Wai-Kit Chan

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Albert Wai-Kit Chan 7/21/99  
Albert Wai-Kit Chan Date  
Reg. No. 36,479

John P. White  
Registration No. 28,678  
Albert Wai-Kit Chan  
Registration No. 36,479  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#19 7/29/99  
T. Gray

Applicants : Philip O. Livingston and Friedhelm Helling

U.S. Serial No.: 08/196,154 Group Unit: 1806

Filed : November 16, 1995 Examiner: A. Caputa

For :  GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-

1185 Avenue of the Americas  
New York, New York 10036  
July 21, 1999

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**AMENDMENT IN RESPONSE TO THE JUNE 19, 1998**  
**FINAL OFFICE ACTION AND SUBMITTED AS A FIRST SUBMISSION**

This Amendment is submitted in response to a June 18, 1998 Final Office Action issued by the United States Patent and Trademark Office and as a first submission pursuant to a Communication Requesting Withdrawal of Finality under 37 C.F.R. 1.129(a) of the an June 18, 1998 Final Office Action and Petition for a Five Month Extension of Time. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

**In the claims:**

Please amend claim 69 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material. Please add new claims 87-96.

--69. (Amended) A composition comprising a GM2 or a GD2 ganglioside conjugated through the ceramide portion of the ganglioside to Keyhole Limpet Hemocyanin or a derivative thereof and a carbohydrate derivable from the bark of a Quillaja saponaria Molina tree, the

D